Mindbreeze and Booz Allen Hamilton join forces to serve the FDA

16 January 2020

Mindbreeze, a leading provider of appliances and cloud services for knowledge management, and Booz Allen Hamilton, a leader in management and technology consulting, are collaborating with the Food and Drug Administration (FDA) to deliver enterprise search capabilities for the Center for Drug Evaluation and Research (CDER) regulatory review community. The intelligent Mindbreeze InSpire solution was successfully launched in October to provide broad search capabilities for critical review information and a decision-support mechanism to aid the review process for the Center’s regulated products.

“We are proud to partner with Mindbreeze and the FDA to deliver leading-edge search capabilities to support the Agency’s important public health mission,” said Dr. Roman Salasznyk, Vice President at Booz Allen. “Our team of technologists and enterprise search experts are committed to transform FDA’s human drug review process leveraging enabling technologies that ultimately help bring live-saving treatments to market with greater speed and efficiency.”